Conmed (CNMD) Tops Q1 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
CONMED (CNMD) PT Raised to $95 at Needham & Company
April 25, 2019 8:26 AM EDTNeedham & Company analyst Mike Matson raised the price target on CONMED (NASDAQ: CNMD) to $95.00 (from $94.00) while maintaining a Buy rating.
The analyst commented, " CNMD's 1Q19 revenue and EPS beat consensus. Given the recent Buffalo Filter acquisition, management provided 2019 revenue guidance and also raised its... More
